SCHEMBL740618

SCHEMBL740618

CCCC(=O)Nc1ccc(NC(=O)COc2ccc(C)c(C)c2)cc1

nearest known ligand 0.74

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
HPGD P15428 2/20 0.74
KMT2A Q03164 6/20 0.67
MEN1 O00255 4/20 0.67
POLB P06746 4/20 0.65
TDP1 Q9NUW8 1/20 0.65
MAPT P10636 5/20 0.65
ALDH1A1 P00352 4/20 0.65
KDM4E B2RXH2 3/20 0.65
USP2 O75604 1/20 0.65
ALOX15 P16050 1/20 0.65
NR4A1 P22736 1/20 0.65
MAPK1 P28482 1/20 0.65
MCL1 Q07820 1/20 0.65
RAB9A P51151 2/20 0.63
NPC1 O15118 1/20 0.63
HSD17B10 Q99714 1/20 0.62
TP53 P04637 1/20 0.60
RXFP1 Q9HBX9 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7825762 0.84 KMT2A (0.81) HPGDKMT2AMEN1POLBMAPT
SCHEMBL15642202 0.81 ALDH1A1 (0.76) HPGDKMT2AMEN1POLBMAPT
SCHEMBL13856491 0.79 MAPT (1.00) HPGDKMT2AMEN1MAPTALDH1A1
SCHEMBL14119591 0.77 ALDH1A1 (1.00) HPGDKMT2AMEN1POLBMAPT
SCHEMBL108275 0.77 HPGD (0.64) HPGDKMT2AMEN1POLBMAPT
SCHEMBL9842944 0.76 POLB (0.77) HPGDKMT2AMEN1POLBTDP1
SCHEMBL6265254 0.76 POLB (0.78) HPGDKMT2AMEN1POLBTDP1
SCHEMBL19490410 0.76 MAPT (0.69) HPGDKMT2AMEN1MAPTALDH1A1
SCHEMBL3416858 0.76 HPGD (0.62) HPGDKMT2AMEN1POLBMAPT
SCHEMBL2947496 0.75 MEN1 (0.79) HPGDKMT2AMEN1POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3079680-A2 COMPOSITIONS AND METHODS FOR TREATING, PREVENTING AND DIAGNOSING CANCER AND OTHER PROLIFERATIVE DISORDERS Angiogenex, Inc. (US) 2016-10-19 EP disclosed
WO-2015089495-A2 COMPOSITIONS AND METHODS FOR TREATING, PREVENTING AND DIAGNOSING CANCER AND OTHER PROLIFERATIVE DISORDERS ANGIOGENEX, INC. (US) 2015-06-18 WO disclosed
US-8138356-B2 Chemical inhibitors of inhibitors of differentiation Angiogeney, Inc. (US) 2012-03-20 US disclosed
US-20090226422-A1 Chemical Inhibitors of Inhibitors of Differentiation ANGIOGENEX 2009-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090226422-A1 Chemical Inhibitors of Inhibitors of Differentiation BRAF, MAPK1, RAF1 HPGD 3243/4885KMT2A 3273/4885MEN1 3968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.